InVivo Therapeutics (NVIVQ) 10-Q 11 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 07, 2020
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	InVivo Therapeutics Holdings Corp.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,882,240
Entity Central Index Key	0001292519
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets $ in Thousands	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Current assets:
Cash and cash equivalents	$ 9,825	$ 6,602
Restricted cash	6	4
Prepaid expenses and other current assets	508	177
Total current assets	10,339	6,783
Property, equipment and leasehold improvements, net	82	73
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,072	1,211
Prepaid clinical trial expenses	1,122	1,122
Other assets	17	26
Total assets	12,742	9,325
Current liabilities:
Accounts payable	518	942
Operating lease liabilities	310	294
Accrued expenses	964	1,427
Total current liabilities	1,792	2,663
Other liabilities	59	59
Operating lease liabilities - non current	861	1,020
Total liabilities	2,712	3,742
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 16,666,667 shares; 4,882,420 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at June 30, 2020; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019	2	2
Additional paid-in capital	233,791	224,741
Accumulated deficit	(223,763)	(219,160)
Total stockholders’ equity	10,030	5,583
Total liabilities and stockholders’ equity	$ 12,742	$ 9,325

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Feb. 11, 2020	Jan. 31, 2020	Dec. 31, 2019	May 31, 2018	Apr. 30, 2018
Common stock, par value (in dollars per share)	$ 0.00001			$ 0.00001
Common stock, authorized	16,666,667	16,666,667	500,000,000	16,666,667	25,000,000	4,000,000
Common stock, issued	4,882,420			550,736
Common stock, outstanding	4,882,420			550,736
Restricted Stock [Member]
Common stock, outstanding	6,886			6,886

Consolidated Statements of Oper

Consolidated Statements of Operations $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares
Operating expenses:
Research and development	$ 940	$ 1,716	$ 1,991	$ 2,826
General and administrative	1,255	1,532	2,632	3,200
Total operating expenses	2,195	3,248	4,623	6,026
Operating loss	(2,195)	(3,248)	(4,623)	(6,026)
Other income / (expense):
Interest income	4	72	18	171
Other income	2	32	2	76
Other income / (expense), net	6	104	20	247
Net loss	$ (2,189)	$ (3,144)	$ (4,603)	$ (5,779)
Net loss per share, basic and diluted (in dollars per share) | $ / shares	$ (0.49)	$ (10.13)	$ (1.70)	$ (18.62)
Weighted average number of common shares outstanding, basic and diluted (In Shares) | shares	4,453,831	310,378	2,714,976	310,363

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2018	$ 1	$ 223,440	$ (207,330)	$ 16,111
Beginning Balance, (in shares) at Dec. 31, 2018	310,330
Share-based compensation expense		135		$ 135
Issuance of common stock upon vesting of restricted stock units (in shares)	48			48
Issuance of common stock under ESPP		1		$ 1
Issuance of common stock under ESPP (in shares)	36
Net loss			(5,779)	(5,779)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2019	$ 1	223,576	(213,109)	10,468
Ending Balance, (in shares) at Jun. 30, 2019	310,414
Stockholders' Equity Attributable to Parent, Beginning Balance at Mar. 31, 2019	$ 1	223,508	(209,965)	13,544
Beginning Balance, (in shares) at Mar. 31, 2019	310,393
Share-based compensation expense		68		$ 68
Issuance of common stock upon vesting of restricted stock units (in shares)	21			21
Net loss			(3,144)	$ (3,144)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2019	$ 1	223,576	(213,109)	10,468
Ending Balance, (in shares) at Jun. 30, 2019	310,414
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2019	$ 2	224,741	(219,160)	$ 5,583
Beginning Balance, (in shares) at Dec. 31, 2019	550,736			550,736
Share-based compensation expense		115		$ 115
Issuance of common stock upon vesting of restricted stock units (in shares)	50			50
Issuance of common stock under ESPP (in shares)	0
Fractional shares issued due to reverse stock split	7,692
Issuance of common stock in public offerings		8,592		$ 8,592
Issuance of common stock in public offerings (in shares)	2,670,853
Issuance of common stock upon exercise of warrants		343		343
Issuance of common stock upon exercise of warrants (in shares)	1,653,089
Net loss			(4,603)	(4,603)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2020	$ 2	233,791	(223,763)	$ 10,030
Ending Balance, (in shares) at Jun. 30, 2020	4,882,420			4,882,420
Stockholders' Equity Attributable to Parent, Beginning Balance at Mar. 31, 2020	$ 2	231,132	(221,574)	$ 9,560
Beginning Balance, (in shares) at Mar. 31, 2020	2,571,553
Share-based compensation expense		45		$ 45
Issuance of common stock upon vesting of restricted stock units (in shares)	50			50
Issuance of common stock in public offerings		2,557		$ 2,557
Issuance of common stock in public offerings (in shares)	1,715,240
Issuance of common stock upon exercise of warrants		57		57
Issuance of common stock upon exercise of warrants (in shares)	595,577
Net loss			(2,189)	(2,189)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2020	$ 2	$ 233,791	$ (223,763)	$ 10,030
Ending Balance, (in shares) at Jun. 30, 2020	4,882,420			4,882,420

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Cash flows from operating activities:
Net loss	$ (4,603)	$ (5,779)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23	32
Amortization of operating lease right-of-use assets	139	131
Share-based compensation expense	115	135
Non-cash investment (income) expense, net		1
Changes in operating assets and liabilities:
Prepaid expenses	(331)	(696)
Accounts payable	(424)	(30)
Operating lease liability	(143)	(9)
Accrued expenses and other liabilities	(463)	(448)
Net cash used in operating activities	(5,687)	(6,663)
Cash flows from investing activities:
Purchases of property and equipment	(23)
Net cash used in investing activities	(23)
Cash flows from financing activities:
Proceeds from issuance of stock under ESPP		1
Proceeds from exercise of warrants	343
Repayment of loan payable		(100)
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs	8,592
Net cash (used in) provided by financing activities	8,935	(99)
Decrease in cash and cash equivalents and restricted cash	3,225	(6,762)
Cash, cash equivalents and restricted cash at beginning of period	6,716	16,774
Cash, cash equivalents and restricted cash at end of period	9,941	10,012
Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Cash paid for interest		1
Fair value of warrants issued in connection with the 2020 Offering	$ 5,907
Right-of-use assets and lease liability recorded upon adoption of ASC 842		$ 1,475

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2020
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS	1. Business InVivo Therapeutics Holdings Corp., including its subsidiary, (the “Company”) is a biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (“SCIs”). The Company’s proprietary technologies incorporate intellectual property that is licensed under an exclusive, worldwide license from Boston Children’s Hospital (“BCH”) and the Massachusetts Institute of Technology (“MIT”), as well as intellectual property that has been developed internally in collaboration with its advisors and partners. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company has historically financed its operations primarily through the sale of equity-related securities. At June 30, 2020, the Company had cash and cash equivalents of $9.8 million. The Company has not achieved profitability and may not be able to realize sufficient revenue to achieve or sustain profitability in the future. The Company does not expect to be profitable in the next several years, but rather expects to incur additional operating losses. The Company has limited liquidity and capital resources and must obtain significant additional capital resources in order to sustain its product development efforts, for acquisition of technologies and intellectual property rights, for preclinical and clinical testing of its anticipated products, pursuit of regulatory approvals, acquisition of capital equipment, laboratory and office facilities, establishment of production capabilities, for selling, general and administrative expenses, and other working capital requirements. The Company expects that it will need additional capital to fund its operations, which it may raise through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances, and licensing arrangements. The Company believes that it can be successful in obtaining additional capital; however, no assurance can be provided that it will be able to do so. There is no assurance, moreover, that any funds raised will be sufficient to enable the Company to attain profitable operations or continue as a going concern. On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The Company is aware that a significant number of its clinical sites have temporarily suspended enrollment into the INSPIRE 2.0 Study at their institution due to the COVID-19 outbreak, and as such, the COVID-19 outbreak has affected and may continue to affect the potential for enrollment in the Company’s INSPIRE 2.0 Study as clinical sites suspend studies in order to manage the pandemic. Aside from the impact on enrollment in the Company’s INSPIRE 2.0 Study, the Company did not experience any significant impact from the COVID-19 outbreak on its financial condition, liquidity, other operations, suppliers, industry, and workforce for the quarter ended June 30, 2020. The full impact of the COVID-19 outbreak continues to evolve as of the date of filing this Quarterly Report on Form 10-Q. The Company is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce, although there remains significant uncertainty related to the public health situation globally. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the ultimate effects of the COVID-19 outbreak on its future results of operations, financial condition, or liquidity in the future. However, as the COVID-19 outbreak continues, it will likely continue to have an adverse effect on enrollment in the Company’s INSPIRE 2.0 Study, and may also have an adverse effect on the Company’s results of future operations, financial position, and liquidity, and even after the COVID-19 outbreak has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Going Concern The Company’s consolidated financial statements as of June 30, 2020 were prepared under the assumption that the Company will continue as a going concern. At June 30, 2020, the Company had cash and cash equivalents of $9.8 million. Given the Company’s development plans, the Company estimates cash resources will be sufficient to fund its operations into the second quarter of 2021. The Company’s ability to continue as a going concern depends on its ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. The COVID-19 outbreak could have a continued adverse impact on economic and market conditions and trigger a period of global economic slowdown, which would impair the Company’s ability to raise needed funds to continue as a going concern. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its unaudited consolidated financial statements, and it is likely that investors will lose all or part of their investment. If the Company seeks additional financing to fund its business activities in the future and there remains substantial doubt about its ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to the Company on commercially reasonable terms or at all. Based on these factors, as of June 30, 2020, management determined that there is substantial doubt regarding the Company’s ability to continue as a going concern. Reverse Stock Split On February 11, 2020, the Company effected a reverse stock split of its common stock, par value $0.00001 per share, at a ratio of 1-for-30 (the “2020 Reverse Stock Split”). As a result of the 2020 Reverse Stock Split, (i) every 30 shares of the issued and outstanding common stock were automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, and (iii) the number of authorized shares of common stock outstanding was proportionally decreased. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these consolidated financial statements were adjusted, on a retroactive basis to reflect the 2020 Reverse Stock Split. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited consolidated financial statements and related footnotes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission (“SEC”) on February 20, 2020. The unaudited consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and its results of operations and cash flows for the interim period presented, and are not necessarily indicative of results for subsequent interim periods or for the full year. The interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and subsequent amendments to the initial guidance: ASU No. 2018-19 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, ASU No. 2019-04 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments”, ASU No. 2019-05 “Financial Instruments-Credit Losses”, ASU No. 2019-11 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses”, ASU No. 2020-02 “Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842)” and ASU No. 2020-03 “Codification Improvements to Financial Instruments, (collectively, “Topic 326”)”. Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for all public business entities, excluding smaller reporting companies, for periods beginning after December 15, 2019 and all other entities beginning after December 15, 2022. The Company early adopted ASU No. 2016-13 and the related amending ASU’s on January 1, 2020, and the adoption did not have a material effect on the Company’s financial position, results of operations or disclosures. In August 2018, the FASB issued ASU No. 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement” which improves the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. The Company adopted ASU No. 2018-13 on January 1, 2020, and the adoption did not have a material effect on the Company’s financial position, results of operations or disclosures. In November 2019, the FASB issued ASU No. 2019-08 “Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements - Share-Based Consideration Payable to a Customer.” ASU No. 2019-08 amends and clarifies ASU No. 2018-07, which we adopted on January 1, 2019, to require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. For entities that have already adopted the amendments in ASU No. 2018-07, the amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU No. 2019-08 on January 1, 2020, and the adoption did not have any impact on the Company’s financial position, results of operations or disclosures. New Accounting Pronouncements Not Yet Adopted In January 2020, the FASB issued ASU No. 2020-01 “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) —clarifying the interactions between Topic 321, Topic 323 and Topic 815 (a consensus of the emerging issues task force)”. The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU No. 2020-01 is effective for the Company beginning in fiscal 2022. The Company is currently in the process of evaluating the effects of this pronouncement on its financial statements.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	6 Months Ended
	Jun. 30, 2020
CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS	2. CASH AND CASH EQUIVALENTS At June 30, 2020 and December 31, 2019, cash equivalents were comprised of money market funds. From time to time, the Company may have cash balances in financial institutions in excess of insurance limits. The Company has not experienced any losses related to these balances. The Company considers only those investments that are highly liquid, readily convertible to cash, and that mature within 3 months from date of purchase to be cash equivalents. Management believes it is not exposed to significant credit risk. Cash and cash equivalents consisted of the following: June 30, December 31, (In thousands) 2020 2019 Cash $ (38) $ (15) Money market funds 9,863 6,617 Total cash and cash equivalents $ 9,825 $ 6,602

RESTRICTED CASH

RESTRICTED CASH	6 Months Ended
	Jun. 30, 2020
RESTRICTED CASH
RESTRICTED CASH	3. RESTRICTED CASH Restricted cash as of June 30, 2020 and December 31, 2019 was $116 thousand and $114 thousand, respectively. Restricted cash as of June 30, 2020 included a $50 thousand security deposit related to the Company’s credit card account, $6 thousand related to 401(k) reserve account and a $60 thousand standby letter of credit in favor of a landlord (see Note 5). Restricted cash as of December 31, 2019 included a $50 thousand security deposit related to the Company’s credit card account, $4 thousand related to 401(k) reserve account and a $60 thousand standby letter of credit in favor of a landlord (see Note 5)

FAIR VALUES OF ASSETS AND LIABI

FAIR VALUES OF ASSETS AND LIABILITIES	6 Months Ended
	Jun. 30, 2020
FAIR VALUES OF ASSETS AND LIABILITIES
FAIR VALUES OF ASSETS AND LIABILITIES	4. FAIR VALUES OF ASSETS AND LIABILITIES The Company groups its assets and liabilities generally measured at fair value into three levels based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. Level 1 — Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2 — Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. Assets and liabilities measured at fair value on a recurring basis are summarized below: At December 31, 2019 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 6,617 $ — $ — $ 6,617 At June 30, 2020 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 9,863 $ — $ — $ 9,863

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	5. COMMITMENTS AND CONTINGENCIES Operating Leases On November 30, 2011, the Company entered into a commercial lease for 26,342 square feet of office, laboratory and manufacturing space in Cambridge, Massachusetts (as amended on September 17, 2012 and October 31, 2017, the “Cambridge Lease”). The term of the Cambridge Lease was 6 years and 3 months, with one 5 ‑ year extension option. On August 21, 2017, the Company exercised its option for the 5-year extension on the Cambridge Lease. The 5-year renewal lease term was set to commence on November 1, 2018 and end on October 31, 2023. The terms of the Cambridge Lease initially required a standby letter of credit in the amount of $311 thousand. On May 3, 2018, the Company assigned the Cambridge Lease to a third party who assumed all of the Company’s remaining rights and obligations under the Cambridge Lease. On the same date as the lease assignment, the Company entered into a sublease for 5,104 square feet of space, originally part of the Cambridge Lease, from the third party to which the Company assigned the Cambridge Lease (the “Current Cambridge Lease”). The Current Cambridge Lease commenced on May 3, 2018 and expires October 31, 2023 and contains rent holiday and rent escalation clauses. The Current Cambridge Lease does not contain any renewal options. In connection with the assignment of the Cambridge Lease and the Current Cambridge Lease, the $311 thousand standby letter of credit was terminated, and a new standby letter of credit was established for $40 thousand. On November 1, 2018, the standby letter of credit was increased to $60 thousand. Under the Current Cambridge Lease, the Company will be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts. These costs are considered to be variable lease payments and are not included in the determination of the lease’s right-of-use asset or lease liability. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: · As the Company’s Current Cambridge Lease does not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. To calculate the present value of remaining lease payments, the Company elected to use an incremental borrowing rate based on the remaining lease term at transition. · Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. · The expected lease terms include noncancelable lease periods . The elements of lease expense are as follows: Lease cost (In thousands) Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating lease cost $ 91 $ 91 $ 182 $ 182 Short-term lease cost 5 6 13 12 Variable lease cost 51 — 76 — Total lease cost $ 147 $ 97 $ 271 $ 194 Other information (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from short term leases $ 5 $ 6 $ 13 $ 12 Operating cash flows from operating leases 93 60 186 60 Total cash paid for leases $ 98 $ 66 $ 199 $ 72 Right-of-use assets obtained in exchange for operating lease liabilities $ — $ — $ — $ — Weighted-average remaining lease term - operating leases 3.3 Years 4.3 Years 3.3 Years 4.3 Years Weighted-average discount rate - operating leases Maturities of lease liabilities due under the Company’s Current Cambridge Lease as of June 30, 2020 is as follows: Leases (In thousands) As of June 30, 2020 2020 (excluding the 6 months ended June 30, 2020) $ 189 2021 386 2022 398 2023 339 Total lease payments 1,312 Less: imputed interest (141) Present value of lease liabilities $ 1,171 Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: Leases (In thousands) Classification June 30, 2020 December 31, 2019 Assets Lease asset, net Operating $ 1,072 $ 1,211 Total lease assets $ 1,072 $ 1,211 Liabilities Current Operating $ 310 $ 294 Non-Current Operating 861 1,020 Total lease liabilities $ 1,171 $ 1,314 Clinical Trial Commitments The Company has engaged and executed contracts with a clinical research organization (“CRO”) consultant to assist with the administration of its ongoing INSPIRE 1.0 and INSPIRE 2.0 clinical trials. As of June 30, 2020, approximately $5.1 million remains to be paid on these contracts over the term of the clinical trials which are expected to be completed in November 2023. The costs may vary depending on actual pass-through expenses incurred to execute the trial. In the event the Company were to terminate the INSPIRE 2.0 trial, certain financial penalties would become payable to the CRO for costs to wind down the terminated trial.

FIXED ASSETS

FIXED ASSETS	6 Months Ended
	Jun. 30, 2020
FIXED ASSETS
FIXED ASSETS	6. FIXED ASSETS Property, equipment, and leasehold improvements, net consisted of the following: June 30, December 31, (In thousands) 2020 2019 Computer software and hardware $ 154 $ 131 Research and lab equipment 520 520 Leasehold improvements 66 66 Property and equipment 740 717 Less accumulated depreciation (658) (644) Property and equipment, net $ 82 $ 73 Depreciation expense for the three and six months ended June 30, 2020, was $7 thousand, and $14 thousand, respectively. Depreciation expense for the three and six months ended June 30, 2019, was $10 thousand, and $22 thousand, respectively. Maintenance and repairs are charged to expense as incurred and any additions or improvements are capitalized.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2020
INTANGIBLE ASSETS
INTANGIBLE ASSETS	7. INTANGIBLE ASSETS Intangible assets, included in “other assets,” consisted of patent licensing fees paid to license intellectual property. In July 2007, the Company entered into a worldwide exclusive license (the “BCH License”) for patents co-owned by BCH and MIT initially covering the use of biopolymers to treat spinal cord injuries, and to promote the survival and proliferation of human stem cells in the spinal cord. During 2011, the BCH License was amended, and the Company obtained additional rights for use in the field of peripheral nerve injuries. The BCH License, as amended, has a 15 ‑ year term, or as long as the life of the last expiring patent right thereunder, whichever is longer, unless terminated earlier by the licensor, under certain conditions as defined in the related license agreement. In connection with the BCH License, the Company paid an initial $75 thousand licensing fee and is required to pay certain annual maintenance fees, milestone payments and royalties. License fees are capitalized and the gross total at June 30, 2020 and December 31, 2019 was $200 thousand. The Company accounts for milestone payments, maintenance fees and royalties when they become due and payable. During the three and six months ended June 30, 2020 and 2019, the Company did not pay any milestone payments. The Company is amortizing the license fee as a research and development expense over the 15– year term of the license. Intangible assets, net consisted of the following: June 30, December 31, (In thousands) 2020 2019 Patent licensing fee $ 200 $ 200 Accumulated amortization (183) (174) Intangible assets, net $ 17 $ 26 Amortization expense during each of the three and six months ended June 30, 2020 and 2019 was $5 thousand and $9 thousand, respectively.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2020
ACCRUED EXPENSES.
ACCRUED EXPENSES	8. ACCRUED EXPENSES Accrued expenses consisted of the following: June 30, December 31, (In thousands) 2020 2019 Compensation $ 406 $ 1,040 Clinical 140 143 Legal 145 37 Other accrued expenses 273 207 Total accrued expenses $ 964 $ 1,427

LOAN PAYABLE

LOAN PAYABLE	6 Months Ended
	Jun. 30, 2020
LOAN PAYABLE
LOAN PAYABLE	9. LOAN PAYABLE In October 2012, the Company entered into a loan agreement with the Massachusetts Development Finance Agency (“MassDev”). The loan agreement provided the Company with a $2.0 million line of credit from the Commonwealth of Massachusetts’ Emerging Technology Fund, with $200 thousand designated to be used for working capital purposes and the remainder to be used for the purchase of capital equipment. The annual interest rate on the loan was fixed at 6.5% with interest-only payments for the first 30 months, commencing on November 1, 2012, and then equal installments of interest and principal over the next 54 months, until the final maturity of the loan in March 2019. Commencing on May 1, 2015, equal monthly payments of $41 thousand were due until loan maturity. In May 2018, in order to obtain the consent of MassDev for facility changes, including the assignment of the Cambridge Lease, and the sale of certain assets, the Company paid down $300 thousand of principal on the MassDev loan. During the six month period ended June 30, 2019, the Company made principal loan payments of $100 thousand. In March 2019, the Company repaid the MassDev loan in full and the loan agreement was terminated. In October 2012, as part of the loan agreement, the Company issued MassDev a 7-year warrant for the purchase of 13 shares of the Company’s common stock with an exercise price of $4,980 per share. The fair value of the warrant was determined to be $32 thousand and was amortized through interest expense over the life of the note. The Company did not record any amortization expense during the three months ended June 30, 2019. For the six months ended June 30, 2019 the Company recorded $1 thousand in amortization expense. This amortization expense was included in interest expense in the Company’s consolidated statements of operations. The Company did not record any amortization expense during the three and six month periods ended June 30, 2020. The equipment line of credit was secured by substantially all the assets of the Company, excluding intellectual property. Interest expense related to this loan for the six month period ended June 30, 2019 was $1 thousand. The Company did not record any interest expense during the three and six month periods ended June 30, 2020.

COMMON STOCK

COMMON STOCK	6 Months Ended
	Jun. 30, 2020
COMMON STOCK.
COMMON STOCK	10. COMMON STOCK In May 2018, the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of authorized common stock from 4,000,000 to 25,000,000 shares of common stock (giving effect to a 1-for-25 reverse stock split effected on April 16, 2018 but not the 2020 Reverse Stock Split). In January 2020, the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of authorized common stock from 25,000,000 to 500,000,000 (without giving effect to the 2020 Reverse Stock Split). On February 11, 2020, the Company effected the 2020 Reverse Stock Split and the number of shares of authorized common stock was reduced to 16,666,667. As of June 30, 2020, and December 31, 2019, 4,882,420 and 550,736 shares were issued and outstanding, respectively. In April 2020, the Company entered into a securities purchase agreement (the "April 2020 Purchase Agreement") with certain institutional investors (the "April 2020 Purchasers"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of 1,715,240 of common stock, at a purchase price per share of $1.75 (the "April 2020 Shares"). The April 2020 Shares were offered by the Company pursuant to a shelf registration statement on Form S-3, which was declared effective by SEC on November 14, 2019 (File No. 333-234353) and a prospectus supplement thereunder. Pursuant to the April 2020 Purchase Agreement, in a concurrent private placement, the Company also issued to the April 2020 Purchasers warrants (the "Series C Warrants") to purchase up to 1,715,240 shares of common stock (the "Private Placement" and together with the April 2020 Registered Offering, the "April 2020 Offerings"). The Series C Warrants are exercisable immediately at an exercise price of $1.62 per share of common stock, subject to adjustment in certain circumstances, and expire on October 17, 2025. In connection with the April 2020 Offerings, the Company also issued to designees of H.C. Wainwright & Co., LLC (“Wainwright”), warrants to purchase an aggregate of 111,491 (“Wainwright April 2020 Placement Agent Warrants”) shares of the Company’s common stock which represents a number of shares of common stock equal to 6.50% of the aggregate number of April 2020 Shares sold in the April 2020 Registered Offering, at an exercise price of $2.1875 per share with a term expiring on April 15, 2025. The net proceeds to the Company, after deducting Wainwright's placement agent fees and other offering expenses payable by the Company, were approximately $2.6 million. The Company assessed whether the Series C Warrants, and the Wainwright April 2020 Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging. As such, the Company concluded that the Series C Warrants and the Wainwright April 2020 Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the Series C warrants was estimated at $2.1 million, using a Black-Scholes model with the following assumptions: expected volatility of 115.84%, risk free interest rate of 0.40%, expected life of 5.5 years and no dividends. The fair value of the Wainwright April 2020 Placement Agent Warrants was estimated at $128 thousand, using a Black-Scholes model with the following assumptions: expected volatility of 116.14%, risk free interest rate of 0.36%, expected life of 5 years and no dividends. During the three months ended June 30, 2020, the Company issued an aggregate of 35,000 shares of common stock upon the exercise of certain of the 2020 Series C warrants for aggregate proceeds of $57 thousand. In March 2020, the Company completed a registered public offering (the “March 2020 Offering”) in which it sold an aggregate of (i) 955,613 shares of common stock, (the “Shares”) at a combined public offering price of $2.75 per share and 2020 Series A Warrant (as defined below), (ii) pre-funded Series B warrants exercisable for an aggregate of 1,589,842 shares of common stock at a combined public offering price of $2.74999 per share and 2020 Series A Warrant (the “2020 Series B Warrants”) and (iii) Series A Warrants exercisable for an aggregate of 2,545,455 shares of common stock (the “2020 Series A Warrants”). The Shares and the 2020 Series B Warrants were each offered together with the 2020 Series A Warrants, but the Shares and 2020 Series B Warrants were issued separately from the 2020 Series A Warrants. Each 2020 Series A Warrant has an exercise price of $2.75 per share, is exercisable immediately and expires in March 2025. Each 2020 Series B Warrant has an exercise price of $0.00001 per share, is exercisable immediately, and expires when exercised in full, subject to certain conditions. In connection with the March 2020 Offering, the Company issued, to designees of Wainwright the placement agent for the March 2020 Offering, warrants (the “Wainwright March 2020 Placement Agent Warrants”) to purchase an aggregate of 165,455 shares of the Company’s common stock, which represents a number of shares of common stock equal to 6.5% of the aggregate number of shares of common stock and 2020 Series B Warrants sold in the March 2020 Offering. The Wainwright March 2020 Placement Agent Warrants have an exercise price of $3.4375 per share, are immediately exercisable and expire in March 2025. The net proceeds to the Company, after deducting Wainwright's placement agent fees and other offering expenses payable by the Company, were approximately $6.0 million. The Company assessed whether the 2020 Series A Warrants, 2020 Series B Warrants and the Wainwright March 2020 Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging. As such, the Company concluded that the 2020 Series A Warrants, 2020 Series B Warrants and the Wainwright March 2020 Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the 2020 Series A warrants and Wainwright March 2020 Placement Agent Warrants was estimated at $3.5 million and $218 thousand, respectively, using a Black-Scholes model with the following assumptions: expected volatility of 115.22%, risk free interest rate of 0.63%, expected life of 5 years and no dividends. The 2020 Series B Warrants had an intrinsic value of approximately $4.4 million. During the three months ended June 30, 2020, the Company issued an aggregate of 560,577 shares of common stock upon the exercise of certain of the pre-funded 2020 Series B warrants for an immaterial amount. During the six months ended June 30, 2020, the Company issued an aggregate of 1,577,114 shares of common stock upon the exercise of certain of the pre-funded 2020 Series B warrants for an immaterial amount. In November 2019, the Company closed a public offering of an aggregate of 233,341 shares of its common stock, at an offering price of $3.60 per share (the offering, the “2019 Offering”). The net proceeds to the Company after deducting placement agent fees and other offering expenses, were $367 thousand. In connection with the 2019 Offering, the Company agreed to issue, and in January 2020 issued, to designees of Wainwright, the placement agent for the 2019 Offering, warrants (the “Placement Agent Warrants”) to purchase an aggregate of 15,168 shares of the Company’s common stock. The Placement Agent Warrants have an exercise price of $4.50 per share, are immediately exercisable and expire in November 2024. The Company assessed whether the Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with ASC Topic 815, Derivatives and Hedging. As such, the Company concluded that the Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the Placement Agent Warrants was estimated at $59 thousand using a Black-Scholes model with the following assumptions: expected volatility of 100.82%, risk free interest rate of 1.61%, expected life of 5 years and no dividends. During the three and six months ended June 30, 2020, there was no exercise activity related to the Placement Agent Warrants. In June 2018, the Company closed an underwritten public offering of an aggregate of 45,950 Common Units, at an offering price of $60.00 each, each comprised of 1 share of the Company’s common stock and 1 Series A warrant to purchase 1 share of common stock. The public offering also included 208,096 pre-funded units at an offering price of $59.70 each, each comprised of 1 pre-funded Series B Warrant, and 1 Series A warrant to purchase 1 share of common stock. Each Series A warrant has an exercise price of $60.00 per share, is exercisable immediately and expires 5 years from the date of issuance. Each Series B warrant had an exercise price of $0.30 per share, was exercisable immediately and would have expired 20 years from the date of issuance. The net proceeds to the Company, after deducting the underwriting discounts and commissions and other offering expenses, were $13.5 million. In September 2018, the Company entered into an Amendment to the Warrant Agency Agreement and Warrants (the “Ladenburg Warrant Amendment”) with Continental Stock Transfer & Trust Company (“Continental”) that amended the Warrant Agency Agreement, by and between the Company and Continental, as Warrant Agent, dated June 25, 2018, and the Series A common stock Purchase Warrant, and the Series B Pre-Funded common stock Purchase Warrant both dated June 25, 2018 (the Series A and Series B Warrant, collectively the “2018 Warrants”). The Ladenburg Warrant Amendment added a provision to each of the warrants that allowed the Company or a successor entity whose stock is not listed on a trading market to, in connection with a Fundamental Transaction (as such term is defined in the 2018 Warrants) that is not within the Company’s control, purchase the warrant from the holder, at the holder’s option, by paying the same form of consideration in the same proportion that is offered to the holders of the Company’s common stock in connection with the Fundamental Transaction, including cash, stock, any combination thereof and any choice of consideration thereof, in an amount equal to the Black-Scholes Value of the remaining unexercised portion of the Warrant on the consummation date of the Fundamental Transaction. The 2018 Warrants were initially classified as liabilities, as a result of the amendment, the Company reassessed the warrant classification and concluded that the warrants qualified for equity classification. The fair value of the amended 2018 Warrants was re-measured immediately prior to the date of the Ladenburg Warrant Amendment with changes in fair value recorded as a loss of $764 thousand in the Company’s consolidated statement of operations and $14.7 million was reclassified to equity. In November 2019, the Company entered into a Second Amendment to Warrant Agency Agreement and Warrants, (“the Second Ladenburg Warrant Amendment”), by and between the Company and Continental, as Warrant Agent, that amended the Series A warrants to reflect a reduced exercise price per share of $6.98 from $60.00. The fair value of the amended Series A warrants was re-measured immediately prior to the date of the Second Ladenburg Warrant Amendment with changes in fair value recorded as incremental expense of $666 thousand in the Company’s consolidated statement of operations. The Company did not issue any shares as a result of either the Series A or Series B warrant exercise activity during the three months ended June 30, 2020. During the six months ended June 30, 2020 the Company issued an aggregate of 40,975 shares of common stock upon the exercise of certain of the Series A warrants for aggregate proceeds of $286 thousand. The Company did not issue any shares as a result of Series B warrant exercise activity during the six months ended June 30, 2020. The Company did not issue any shares as a result of either the Series A or Series B warrant exercise activity during the three and six months ended June 30, 2019. There are no outstanding Series B warrants as of June 30, 2020. In January 2018, the Company entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “RRA”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which it had the right to sell up to $15 million, in shares of our common stock,, to Lincoln Park over a 24 month period, subject to certain limitations and conditions set forth in the Purchase Agreement and RRA. On May 30, 2018, the Company’s stockholders approved to increase the issuance and sale by the Company to Lincoln Park, including the Company’s prior issuances and sales of shares of common stock to Lincoln Park since January 2018, of up to 40,000 shares of common stock. In accordance with the terms of the Purchase Agreement, at the time the Company signed the Purchase Agreement and the RRA, it issued 574 shares to Lincoln Park as consideration for its commitment to purchase shares of the Company’s common stock under the Purchase Agreement and recorded $627 thousand in deferred offering costs of which the full amount was capitalized into additional paid-in capital in 2018. The Company did not sell any shares to Lincoln Park during the three months ended June 30, 2019. In May 2019, the Company terminated the Purchase Agreement with Lincoln Park. In May 2018, the Company’s Board of Directors approved to increase the number of shares of common stock reserved under the 401(k) Plan by 134 shares, bringing the aggregate number of shares of common stock eligible for distribution pursuant to the 401(k) Plan as of that date to 137 shares. In the second quarter of 2018 the Company revised its 401(k)-matching policy to move from share matching to cash-based matching. During the three and six months ended June 30, 2019, the Company contributed $19 thousand and $31 thousand respectively, in cash as a matching contributions to employee 401(k) accounts. During the three and six months ended June 30, 2020, the Company contributed $16 thousand and $35 thousand respectively, in cash as a matching contribution to employee 401(k) accounts. In January 2019, 36 shares that were purchased in the offering period commencing on July 1, 2018 and ending on December 31, 2018 were issued under the ESPP. During the three and six months ended June 30, 2020, the Company did not issue any shares under the Company’s Employee Stock Purchase Plan (the “ESPP”). During the three months ended June 30, 2019, the Company issued an aggregate of 21 shares of common stock respectively, upon vesting of restricted stock units. During the six months ended June 30, 2019, the Company issued an aggregate of 48 shares of common stock respectively, upon vesting of restricted stock units. During the three and six months ended June 30, 2020, the Company issued an aggregate of 50 shares of common stock upon vesting of restricted stock units. During the six months ended June 30, 2020, as part of the adjustment to reflect the 2020 Reverse Stock Split, the Company issued 7,692 shares of common stock to account for the fractional roundup of shareholders.

SHARE-BASED COMPENSATION, STOCK

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES	6 Months Ended
	Jun. 30, 2020
SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES
SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES	11. STOCK-BASED COMPENSATION In 2007, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2007 Employee, Director and Consultant Stock Plan (the “2007 Plan”). The 2007 Plan provided that the Company’s Board of Directors (or committees and/or executive officers delegated by the Board of Directors) could grant incentive and nonqualified stock options to the Company’s employees, officers, directors, consultants and advisors. On October 26, 2010, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2010 Equity Incentive Plan (as subsequently amended, the “2010 Plan”). The 2010 Plan provided for grants of incentive stock options to employees, and nonqualified stock options and restricted common stock to employees, consultants, and non-employee directors of the Company. In April 2015, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for grants of incentive stock options to employees, and nonqualified stock options, restricted common stock, restricted stock units (“RSUs”), and stock appreciation rights to employees, consultants, and non-employee directors of the Company. Upon approval of the 2015 Plan by the Company’s shareholders on June 16, 2015, the 2010 Plan was terminated and no additional shares or share awards have been subsequently granted under the 2010 Plan. In March 2019, the Company’s Board approved, and recommended to the Company’s shareholders for approval, an amendment to the 2015 Plan (the “2015 Plan Amendment”), and on January 21, 2020, the Company’ shareholders subsequently approved the 2015 Plan Amendment. The 2015 Plan Amendment increased the maximum number of shares reserved for issuance under the 2015 Plan by 26,667 shares to a total of 32,000 shares. As of June 30, 2020, the total number of shares available to be issued under the 2015 Plan was 26,670 shares, consisting of (i) 5,333 shares initially authorized under the 2015 Plan shares plus, (ii) the shares that remained available for grant under the 2010 Plan at the time of its termination adjusted for cumulative cancellations, forfeitures and issuances from the 2010 Plan and 2015 Plan plus, (iii) the 26,667 shares approved for increase during the January 2020 shareholders meeting. Options issued under the 2007 Plan, 2010 Plan, and 2015 Plan (collectively, the “Plans”) are exercisable for up to 10 years from the date of issuance. In March 2015, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved the ESPP. The ESPP allows employees to buy company stock twice per year through after-tax payroll deductions at a discount from market. The Company’s Board of Directors initially authorized 250 shares for issuance under the ESPP. Commencing on the first day of the year ended December 31, 2016 and on the first day of each year thereafter during the term of the ESPP, the number of shares of common stock reserved for issuance shall be increased by the lesser of (i) 1% of the Company’s outstanding shares of common stock on such date, (ii) 67 shares or (iii) a lesser amount determined by the Board of Directors. Under the terms of the ESPP, in no event shall the aggregate number of shares reserved for issuance during the term of the ESPP exceed 1,667 shares. As of both June 30, 2020 and December 31, 2019, there were 264 shares reserved for issuance under the ESPP. In January 2019, 36 shares that were purchased in the offering period commencing on July 1, 2018 and ending on December 31, 2018 were issued under the ESPP. The ESPP is considered a compensatory plan with the related compensation cost recognized over each 6 month offering period. None of the Company’s employees participated in the ESPP plan in the current offering period and consequently no compensation expense was recorded during the six month period ended June 30, 2020. Stock-based compensation For the three month periods ended June 30, 2020 and 2019, the Company recorded stock-based compensation expense of $45 thousand and $68 thousand, respectively. For the six month periods ended June 30, 2020 and 2019, the Company recorded stock-based compensation expense of $115 thousand and $135 thousand, respectively. Stock-based compensation recognized was classified in the consolidated statements of operations as follows: (In thousands) Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Research and development $ 7 $ 26 $ 27 $ 50 General and administrative 38 42 88 85 Total $ 45 $ 68 $ 115 $ 135 The fair value of each option award is estimated on the date of grant using the Black ‑ Scholes option pricing model, which uses the following assumptions; (i) Risk-free interest rate, (ii) Expected dividend yield, (iii) Expected term and (iv) Expected volatility. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises within the valuation model. The expected term of options granted under the Plans, all of which qualify as “plain vanilla,” is based on the average of the contractual term (10 years) and the vesting period (generally, 48 months). For non ‑ employee options, the expected term is the contractual term. The risk ‑ free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. The impact of forfeitures on compensation expense is recorded as they occur. The Company grants RSUs and restricted stock awards (“RSAs”), collectively referred to as restricted securities under its the 2015 Equity Incentive Plan. These restricted securities, generally vest over a three-year period, contingent on the recipient’s continued employment. Prior to vesting, all RSAs have the right to vote and receive dividends under the 2015 Equity Incentive Plan; however, the Company’s form of Restricted Stock Agreement provides that the payment of dividends on unvested RSAs shall be deferred until such time as the shares vest. The grant date fair value of these awards is based on the fair market value of our common stock on the date of grant. The Company did not grant any awards during the three and six months ended June 30, 2020. The assumptions used principally in determining the fair value of options granted during the three and six months ended June 30, 2019 were as follows: June 30, 2019 Risk-free interest rate 2.55% Expected dividend yield 0% Expected term (employee grants) 6 Years Expected volatility 105% Stock options A summary of option activity as of June 30, 2020 and changes for the six month period then ended are presented below: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Shares Price Term in Years Value Outstanding at December 31, 2019 4,187 $ 1,077.78 $ — Granted — $ — Expired — $ — Cancelled/Forfeited — $ — Outstanding at June 30, 2020 4,187 $ 1,077.78 7.65 — Vested and Exercisable at June 30, 2020 2,061 $ 2,022.20 6.83 — The total fair value of options that vested in the three months ended June 30, 2020 and 2019 was $24 thousand and $33 thousand, respectively. The total fair value of options that vested in the six months ended June 30, 2020 and 2019 was $80 thousand and $69 thousand, respectively. For the three month periods ended June 30, 2020 and 2019, the Company recorded stock-based compensation expense of $21 thousand and $43 thousand, respectively related to stock options. For the six month periods ended June 30, 2020 and 2019, the Company recorded stock-based compensation expense of $64 thousand and $84 thousand, respectively related to stock options. As of June 30, 2020, total unrecognized compensation expense related to non-vested share-based option compensation arrangements amounted to $116 thousand and is estimated to be recognized over a period of 1.21 years. Restricted Securities The following table summarizes the restricted securities activity under the 2015 Plan during the six month period ended June 30, 2020: Weighted-Average Restricted Securities Number of Grants Grant Date Fair Value Unvested balance at December 31, 2019 7,086 $ 33.78 Granted — $ Vested (50) $ Unvested balance at June 30, 2020 7,036 $ 29.34 For the three month periods ended June 30, 2020, and 2019, the Company recorded stock-based compensation expense of $24 thousand and $25 thousand, respectively, related to the time-based restricted securities. For the six month periods ended June 30, 2020, and 2019, the Company recorded stock-based compensation expense of $51 thousand and $51 thousand, respectively, related to the time-based restricted securities. As of June 30, 2020, total unrecognized compensation expense related to non-vested restricted securities amounted to $177 thousand which the Company expects to recognize over a remaining weighted-average of 1.81 years. All the restricted securities that remain unvested and outstanding at June 30, 2020 are subject to time-based vesting.

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2020
WARRANTS
WARRANTS	12. WARRANTS The following table presents information about warrants to purchase common stock issued and outstanding at June 30, 2020: Number of Exercise Price Year Issued Defined Name Classification Warrants as of June 30, 2020 Date of Expiration 2014 2014 Warrants Equity 11 $ 352.50 5/9/2021 2016 2016 Warrants Equity 2,865 $ 7,500.00 3/18/2021 2018 2018 Series A Warrants Equity 211,921 $ 6.98 6/25/2023 2019 Placement Agent Warrants Equity 15,168 $ 4.50 11/21/2024 2020 2020 Series A Warrants Equity 2,545,455 $ 2.75 3/10/2025 2020 Wainwright March 2020 Placement Agent Warrants Equity 165,455 $ 3.4375 3/5/2025 2020 2020 Series B Warrants Equity 12,728 $ 0.00001 Until Fully Exercised 2020 2020 Series C Warrants Equity 1,680,240 $ 1.62 10/17/2025 2020 Wainwright April 2020 Placement Agent Warrants Equity 111,491 $ 2.1875 4/15/2025 Total 4,745,334 Weighted average exercise price $ 7.08 Weighted average life in years 4.82

NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE	6 Months Ended
	Jun. 30, 2020
NET LOSS PER COMMON SHARE
NET LOSS PER COMMON SHARE	13. NET LOSS PER COMMON SHARE Basic and diluted net loss per share of common stock has been computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock is computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. In a net loss period, options, warrants, unvested restricted securities and convertible securities are anti-dilutive and, therefore, excluded from diluted loss per share calculations. For the three month periods ended June 30, 2020 and 2019, the following potentially dilutive securities were not included in the computation of net loss per share because the effect would be anti-dilutive: June 30, 2020 2019 Warrants 4,745,334 255,781 Stock options 4,187 4,187 Unvested RSUs 150 293 Unvested RSAs 6,886 — Total potentially dilutive securities 4,756,557 260,261

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS On August 4, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of authorized common stock from 16,666,667 to 50,000,000 shares. In addition, at the Annual Meeting, the Company’s stockholders approved an amendment to the 2015 Plan to increase the number of shares available for issuance thereunder by 400,000 shares.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2020
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
Going Concern	Going Concern The Company’s consolidated financial statements as of June 30, 2020 were prepared under the assumption that the Company will continue as a going concern. At June 30, 2020, the Company had cash and cash equivalents of $9.8 million. Given the Company’s development plans, the Company estimates cash resources will be sufficient to fund its operations into the second quarter of 2021. The Company’s ability to continue as a going concern depends on its ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. The COVID-19 outbreak could have a continued adverse impact on economic and market conditions and trigger a period of global economic slowdown, which would impair the Company’s ability to raise needed funds to continue as a going concern. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its unaudited consolidated financial statements, and it is likely that investors will lose all or part of their investment. If the Company seeks additional financing to fund its business activities in the future and there remains substantial doubt about its ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to the Company on commercially reasonable terms or at all. Based on these factors, as of June 30, 2020, management determined that there is substantial doubt regarding the Company’s ability to continue as a going concern.
Reverse Stock Split	Reverse Stock Split On February 11, 2020, the Company effected a reverse stock split of its common stock, par value $0.00001 per share, at a ratio of 1-for-30 (the “2020 Reverse Stock Split”). As a result of the 2020 Reverse Stock Split, (i) every 30 shares of the issued and outstanding common stock were automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, and (iii) the number of authorized shares of common stock outstanding was proportionally decreased. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these consolidated financial statements were adjusted, on a retroactive basis to reflect the 2020 Reverse Stock Split.
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited consolidated financial statements and related footnotes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission (“SEC”) on February 20, 2020. The unaudited consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and its results of operations and cash flows for the interim period presented, and are not necessarily indicative of results for subsequent interim periods or for the full year. The interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and subsequent amendments to the initial guidance: ASU No. 2018-19 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, ASU No. 2019-04 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments”, ASU No. 2019-05 “Financial Instruments-Credit Losses”, ASU No. 2019-11 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses”, ASU No. 2020-02 “Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842)” and ASU No. 2020-03 “Codification Improvements to Financial Instruments, (collectively, “Topic 326”)”. Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for all public business entities, excluding smaller reporting companies, for periods beginning after December 15, 2019 and all other entities beginning after December 15, 2022. The Company early adopted ASU No. 2016-13 and the related amending ASU’s on January 1, 2020, and the adoption did not have a material effect on the Company’s financial position, results of operations or disclosures. In August 2018, the FASB issued ASU No. 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement” which improves the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. The Company adopted ASU No. 2018-13 on January 1, 2020, and the adoption did not have a material effect on the Company’s financial position, results of operations or disclosures. In November 2019, the FASB issued ASU No. 2019-08 “Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements - Share-Based Consideration Payable to a Customer.” ASU No. 2019-08 amends and clarifies ASU No. 2018-07, which we adopted on January 1, 2019, to require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. For entities that have already adopted the amendments in ASU No. 2018-07, the amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU No. 2019-08 on January 1, 2020, and the adoption did not have any impact on the Company’s financial position, results of operations or disclosures. New Accounting Pronouncements Not Yet Adopted In January 2020, the FASB issued ASU No. 2020-01 “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) —clarifying the interactions between Topic 321, Topic 323 and Topic 815 (a consensus of the emerging issues task force)”. The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU No. 2020-01 is effective for the Company beginning in fiscal 2022. The Company is currently in the process of evaluating the effects of this pronouncement on its financial statements.

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	6 Months Ended
	Jun. 30, 2020
CASH AND CASH EQUIVALENTS
Schedule of cash and cash equivalents	June 30, December 31, (In thousands) 2020 2019 Cash $ (38) $ (15) Money market funds 9,863 6,617 Total cash and cash equivalents $ 9,825 $ 6,602

FAIR VALUES OF ASSETS AND LIA_2

FAIR VALUES OF ASSETS AND LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2020
FAIR VALUES OF ASSETS AND LIABILITIES
Summary of assets and liabilities measured at fair value on a recurring basis	At December 31, 2019 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 6,617 $ — $ — $ 6,617 At June 30, 2020 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 9,863 $ — $ — $ 9,863

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2020
COMMITMENTS AND CONTINGENCIES
Schedule of lease cost	Lease cost (In thousands) Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating lease cost $ 91 $ 91 $ 182 $ 182 Short-term lease cost 5 6 13 12 Variable lease cost 51 — 76 — Total lease cost $ 147 $ 97 $ 271 $ 194 Other information (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from short term leases $ 5 $ 6 $ 13 $ 12 Operating cash flows from operating leases 93 60 186 60 Total cash paid for leases $ 98 $ 66 $ 199 $ 72 Right-of-use assets obtained in exchange for operating lease liabilities $ — $ — $ — $ — Weighted-average remaining lease term - operating leases 3.3 Years 4.3 Years 3.3 Years 4.3 Years Weighted-average discount rate - operating leases
Schedule of maturities of lease liabilities	Leases (In thousands) As of June 30, 2020 2020 (excluding the 6 months ended June 30, 2020) $ 189 2021 386 2022 398 2023 339 Total lease payments 1,312 Less: imputed interest (141) Present value of lease liabilities $ 1,171
Schedule of balance sheet information	Leases (In thousands) Classification June 30, 2020 December 31, 2019 Assets Lease asset, net Operating $ 1,072 $ 1,211 Total lease assets $ 1,072 $ 1,211 Liabilities Current Operating $ 310 $ 294 Non-Current Operating 861 1,020 Total lease liabilities $ 1,171 $ 1,314

FIXED ASSETS (Tables)

FIXED ASSETS (Tables)	6 Months Ended
	Jun. 30, 2020
FIXED ASSETS
Schedule of property and equipment, net	June 30, December 31, (In thousands) 2020 2019 Computer software and hardware $ 154 $ 131 Research and lab equipment 520 520 Leasehold improvements 66 66 Property and equipment 740 717 Less accumulated depreciation (658) (644) Property and equipment, net $ 82 $ 73

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2020
INTANGIBLE ASSETS
Summary of intangible assets	June 30, December 31, (In thousands) 2020 2019 Patent licensing fee $ 200 $ 200 Accumulated amortization (183) (174) Intangible assets, net $ 17 $ 26

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2020
ACCRUED EXPENSES.
Summary of accrued expenses	June 30, December 31, (In thousands) 2020 2019 Compensation $ 406 $ 1,040 Clinical 140 143 Legal 145 37 Other accrued expenses 273 207 Total accrued expenses $ 964 $ 1,427

SHARE-BASED COMPENSATION, STO_2

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2020
SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES
Schedule of stock-based compensation	Stock-based compensation recognized was classified in the consolidated statements of operations as follows: (In thousands) Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Research and development $ 7 $ 26 $ 27 $ 50 General and administrative 38 42 88 85 Total $ 45 $ 68 $ 115 $ 135
Schedule of assumptions used principally in determining the fair value of options granted	The assumptions used principally in determining the fair value of options granted during the three and six months ended June 30, 2019 were as follows: June 30, 2019 Risk-free interest rate 2.55% Expected dividend yield 0% Expected term (employee grants) 6 Years Expected volatility 105%
Summary of option activity	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Shares Price Term in Years Value Outstanding at December 31, 2019 4,187 $ 1,077.78 $ — Granted — $ — Expired — $ — Cancelled/Forfeited — $ — Outstanding at June 30, 2020 4,187 $ 1,077.78 7.65 — Vested and Exercisable at June 30, 2020 2,061 $ 2,022.20 6.83 —
Summary of restricted stock unit activity	Weighted-Average Restricted Securities Number of Grants Grant Date Fair Value Unvested balance at December 31, 2019 7,086 $ 33.78 Granted — $ Vested (50) $ Unvested balance at June 30, 2020 7,036 $ 29.34

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2020
WARRANTS
Schedule of information about warrants to purchase common stock issued and outstanding	Number of Exercise Price Year Issued Defined Name Classification Warrants as of June 30, 2020 Date of Expiration 2014 2014 Warrants Equity 11 $ 352.50 5/9/2021 2016 2016 Warrants Equity 2,865 $ 7,500.00 3/18/2021 2018 2018 Series A Warrants Equity 211,921 $ 6.98 6/25/2023 2019 Placement Agent Warrants Equity 15,168 $ 4.50 11/21/2024 2020 2020 Series A Warrants Equity 2,545,455 $ 2.75 3/10/2025 2020 Wainwright March 2020 Placement Agent Warrants Equity 165,455 $ 3.4375 3/5/2025 2020 2020 Series B Warrants Equity 12,728 $ 0.00001 Until Fully Exercised 2020 2020 Series C Warrants Equity 1,680,240 $ 1.62 10/17/2025 2020 Wainwright April 2020 Placement Agent Warrants Equity 111,491 $ 2.1875 4/15/2025 Total 4,745,334 Weighted average exercise price $ 7.08 Weighted average life in years 4.82

NET LOSS PER COMMON SHARE (Tabl

NET LOSS PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2020
NET LOSS PER COMMON SHARE
Schedule of potentially dilutive securities not included in the computation of net loss per share because effect would be anti-dilutive	June 30, 2020 2019 Warrants 4,745,334 255,781 Stock options 4,187 4,187 Unvested RSUs 150 293 Unvested RSAs 6,886 — Total potentially dilutive securities 4,756,557 260,261

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS - Reverse Stock Split (Details) $ / shares in Units, $ in Thousands	Feb. 11, 2020	Apr. 16, 2018	Jun. 30, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
Cash and cash equivalents | $			$ 9,825	$ 6,602
Common stock, par value (in dollars per share) | $ / shares			$ 0.00001	$ 0.00001
Reverse stock split ratio	0.0333	0.04
Going concern			true

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
Cash and cash equivalents	$ 9,825	$ 6,602
Operating lease right-of-use assets	1,072	1,211
Operating lease liabilities	$ 1,171	$ 1,314
Going concern	true

CASH AND CASH EQUIVALENTS - CAS

CASH AND CASH EQUIVALENTS - CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CASH AND CASH EQUIVALENTS
Cash	$ (38)	$ (15)
Money market funds	9,863	6,617
Total cash and cash equivalents	$ 9,825	$ 6,602

RESTRICTED CASH (Details)

RESTRICTED CASH (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Restricted cash
Restricted cash	$ 116	$ 114
Security deposit related to credit card account
Restricted cash
Restricted cash	50	50
401K reserve account
Restricted cash
Restricted cash	6	4
Standby letter of credit
Restricted cash
Restricted cash	$ 60	$ 60

FAIR VALUES OF ASSETS AND LIA_3

FAIR VALUES OF ASSETS AND LIABILITIES (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets and liabilities measured at fair value on a recurring basis
Cash equivalents	$ 9,863	$ 6,617
Level 1
Assets and liabilities measured at fair value on a recurring basis
Cash equivalents	$ 9,863	$ 6,617

COMMITMENTS AND CONTINGENCIES,

COMMITMENTS AND CONTINGENCIES, LEASES (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)claim	Nov. 01, 2018USD ($)	May 03, 2018USD ($)ft²	Nov. 30, 2011USD ($)ft²
Lessee, Lease, Description [Line Items]
Costs expected to be paid to clinical research organization | $	$ 5,100
Cambridge Lease
Lessee, Lease, Description [Line Items]
Lease space (in square feet) | ft²				26,342
Term of commercial lease	6 years 3 months
Number of options to extend lease | claim	1
Term of lease extension option	5 years
Standby letter of credit | $		$ 60	$ 40	$ 311
Cambridge Lease | Sublease
Lessee, Lease, Description [Line Items]
Lease space (in square feet) | ft²			5,104

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES, LEASE EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lease expense
Operating lease cost	$ 91	$ 91	$ 182	$ 182
Short-term lease cost	5	6	13	12
Variable lease cost	51		76
Total lease cost	$ 147	$ 97	$ 271	$ 194

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES, LEASE OTHER INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
COMMITMENTS AND CONTINGENCIES
Operating cash flows from short term leases	$ 5	$ 6	$ 13	$ 12
Operating cash flows from operating leases	93	60	186	60
Total cash paid for leases	$ 98	$ 66	$ 199	72
Right-of-use assets obtained in exchange for new operating lease liabilities				$ 1,475
Weighted-average remaining lease term - operating leases (years)	3 years 3 months 18 days	4 years 3 months 18 days	3 years 3 months 18 days	4 years 3 months 18 days
Weighted-average discount rate - operating leases	7.00%	7.00%	7.00%	7.00%

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES, MATURITIES OF LEASE LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Maturities of lease liabilities
2020 (excluding the 3 months ended March 31, 2019)	$ 189
2021	386
2022	398
2023	339
Total lease payments	1,312
Less : Interest	(141)
Present value of lease liabilities	$ 1,171	$ 1,314

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES, LEASE CLASSIFICATION (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
COMMITMENTS AND CONTINGENCIES
Operating Lease, Right-of-Use Asset	$ 1,072	$ 1,211
Financial position	us-gaap:OperatingLeaseRightOfUseAsset
Total lease assets	$ 1,072	1,211
Operating Liabilities - Current	$ 310	294
Financial position	Operating Liabilities - Current
Operating Liabilities - Non Current	$ 861	1,020
Financial position	us-gaap:OperatingLeaseLiabilityNoncurrent
Total Operating Liabilities	$ 1,171	$ 1,314
Financial position	us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent

FIXED ASSETS, SCHEDULE (Details

FIXED ASSETS, SCHEDULE (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and equipment
Property and equipment	$ 740	$ 717
Less accumulated depreciation and amortization	(658)	(644)
Property and equipment, net	82	73
Computer software and hardware
Property and equipment
Property and equipment	154	131
Research and lab equipment
Property and equipment
Property and equipment	520	520
Leasehold improvements
Property and equipment
Property and equipment	$ 66	$ 66

FIXED ASSETS (Details)

FIXED ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Depreciation
Depreciation expense	$ 7	$ 10	$ 14	$ 22

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jul. 31, 2007
Intangible assets
Useful life	15 years
Accumulated amortization	$ (183)	$ (174)
Intangible assets, net	17	26
BCH License [Member]
Intangible assets
Intangible assets - gross	200	200	$ 75
Patent licensing fee
Intangible assets
Intangible assets - gross	$ 200	$ 200

INTANGIBLE ASSETS, AMORTIZATION

INTANGIBLE ASSETS, AMORTIZATION (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Amortization
Amortization expense	$ 5	$ 9

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
ACCRUED EXPENSES.
Compensation	$ 406	$ 1,040
Clinical	140	143
Legal	145	37
Other accrued expenses	273	207
Total accrued expenses	$ 964	$ 1,427

LOAN PAYABLE (Details)

LOAN PAYABLE (Details) - USD ($) $ / shares in Units, $ in Thousands	May 01, 2015	May 31, 2018	Oct. 31, 2012	Jun. 30, 2020	Jun. 30, 2019
Loans Payable
Number of warrants outstanding				4,745,334
Interest expense					$ 1
MassDev
Loans Payable
Line of credit, maximum			$ 2,000
Line of credit for working capital purpose			$ 200
Fixed interest rate (as a percent)			6.50%
Period for interest-only payments			30 months
Period for charging equal installments of interest and principal			54 months
Maturity date			Mar. 1, 2019
Commencement date of monthly installments	May 1, 2015
Amount of monthly payment	$ 41
Repayment of principal		$ 300		$ 100
Number of warrants outstanding			13
Warrant period			7 years
Exercise price of warrant (in dollars per share)			$ 4,980
Fair value of warrants			$ 32
Amortization				0	$ 1
Interest expense				$ 0

COMMON STOCK, AUTHORIZED (Detai

COMMON STOCK, AUTHORIZED (Details) - shares	Aug. 04, 2020	Jun. 30, 2020	Feb. 11, 2020	Jan. 31, 2020	Dec. 31, 2019	May 31, 2018	Apr. 30, 2018
Common stock, number of shares, par value and other disclosures
Common stock, authorized		16,666,667	16,666,667	500,000,000	16,666,667	25,000,000	4,000,000
Common stock, issued		4,882,420			550,736
Common stock, outstanding		4,882,420			550,736
Subsequent event
Common stock, number of shares, par value and other disclosures
Common stock, authorized	50,000,000

COMMON STOCK, TRANSACTIONS (Det

COMMON STOCK, TRANSACTIONS (Details)

May 30, 2018USD ($)shares

Apr. 30, 2020USD ($)$ / sharesshares

Mar. 31, 2020USD ($)$ / sharesshares

Nov. 30, 2019USD ($)$ / sharesshares

Sep. 30, 2018USD ($)

Jun. 30, 2018USD ($)$ / sharesshares

May 31, 2018shares

Jan. 31, 2018USD ($)

Jun. 30, 2020USD ($)Y$ / sharesshares

Jun. 30, 2019USD ($)shares

Jun. 30, 2020USD ($)Y$ / sharesshares

Jun. 30, 2019USD ($)shares

Dec. 31, 2019$ / shares

Common stock disclosures

Common stock, par value (in dollars per share) | $ / shares

$ 0.00001

$ 0.00001

$ 0.00001

Proceeds from issuance of common stock and warrants, net of issuance costs

$ 8,592,000

Proceeds from exercise of warrants

$ 343,000

Number of Warrants | shares

4,745,334

4,745,334

April 2020 Shares [Member]

Common stock disclosures

Number of shares issued (in shares) | shares

1,715,240

Equity issuance (in price per unit) | $ / shares

$ 1.75

Proceeds from issuance of common stock

$ 2,600,000

Expected volatility

Common stock disclosures

Fair value assumptions

115.22

115.22

Risk-free interest rate

Common stock disclosures

Fair value assumptions

0.63

0.63

Contractual term

Common stock disclosures

Fair value assumptions | Y

5

5

Expected dividend yield

Common stock disclosures

Fair value assumptions

0

0

401(k)

Common stock disclosures

Company contributions to employee 401(k) accounts

$ 16,000

$ 19,000

$ 35,000

$ 31,000

April 2020 Warrants

Common stock disclosures

Number of shares into which a warrant may be converted | shares

1,715,240

Exercise price (in dollars per unit) | $ / shares

$ 1.62

Fair value of warrants

$ 2,100,000

Proceeds from exercise of warrants

$ 57,000

Shares issued on exercise of warrants | shares

35,000

April 2020 Warrants | Expected volatility

Common stock disclosures

Fair value assumptions

115.84

April 2020 Warrants | Risk-free interest rate

Common stock disclosures

Fair value assumptions

0.40

April 2020 Warrants | Contractual term

Common stock disclosures

Fair value assumptions

5.5

April 2020 Warrants | Expected dividend yield

Common stock disclosures

Fair value assumptions

0

2018 Series A Warrant

Common stock disclosures

Exercise price (in dollars per unit) | $ / shares

$ 6.98

$ 6.98

$ 6.98

Number of Warrants | shares

211,921

211,921

Series B Warrants 2020 [Member]

Common stock disclosures

Exercise price (in dollars per unit) | $ / shares

$ 0.00001

Intrinsic value

$ 4,400,000

$ 4,400,000

Number of Warrants | shares

1,589,842

Shares issued on exercise of warrants | shares

560,577

1,577,114

Series A Warrants [Member]

Common stock disclosures

Exercise price (in dollars per unit) | $ / shares

$ 2.75

Fair value of warrants

$ 3,500,000

$ 3,500,000

Number of Warrants | shares

2,545,455

Wainwright 2020 Placement Agent Warrants [Member]

Common stock disclosures

Number of shares into which a warrant may be converted | shares

111,491

Exercise price (in dollars per unit) | $ / shares

$ 2.1875

Fair value of warrants

$ 128,000

218,000

218,000

Wainwright 2020 Placement Agent Warrants [Member] | Expected volatility

Common stock disclosures

Fair value assumptions

116.14

Wainwright 2020 Placement Agent Warrants [Member] | Risk-free interest rate

Common stock disclosures

Fair value assumptions

0.36

Wainwright 2020 Placement Agent Warrants [Member] | Contractual term

Common stock disclosures

Fair value assumptions

5

Wainwright 2020 Placement Agent Warrants [Member] | Expected dividend yield

Common stock disclosures

Fair value assumptions

0

Placement Agent Warrants

Common stock disclosures

Percentage of aggregate number of shares available

6.50%

Exercise price (in dollars per unit) | $ / shares

$ 3.4375

Fair value of warrants

$ 59,000

$ 59,000

Number of Warrants | shares

165,455

Placement Agent Warrants | Expected volatility

Common stock disclosures

Fair value assumptions

100.82

100.82

Placement Agent Warrants | Risk-free interest rate

Common stock disclosures

Fair value assumptions

1.61

1.61

Placement Agent Warrants | Contractual term

Common stock disclosures

Fair value assumptions | Y

5

5

Placement Agent Warrants | Expected dividend yield

Common stock disclosures

Fair value assumptions

0

0

Common Stock

Common stock disclosures

Number of shares issued (in shares) | shares

1,715,240

2,670,853

Common Stock | 401(k)

Common stock disclosures

Aggregate number of shares reserved for issuance | shares

137

Number of additional shares reserved | shares

134

Underwritten Public Offering, June 2018

Common stock disclosures

Proceeds from issuance of common stock and warrants, net of issuance costs

$ 13,500,000

Underwritten Public Offering, June 2018 | 2018 Series A Warrant

Common stock disclosures

Number of shares/warrants comprised in a unit (in shares) | shares

1

Warrant expiration term (in years)

5 years

Exercise price (in dollars per unit) | $ / shares

$ 60

Underwritten Public Offering, June 2018 | 2018 Series B Warrant Exercise price $.01

Common stock disclosures

Warrant expiration term (in years)

20 years

Exercise price (in dollars per unit) | $ / shares

$ 0.30

Number of Warrants | shares

0

0

Underwritten Public Offering, June 2018 | Common Stock

Common stock disclosures

Number of shares/warrants comprised in a unit (in shares) | shares

1

Number of shares of common stock to be purchased by each warrant | shares

1

Underwritten Public Offering, June 2018 | Common Stock And Warrants

Common stock disclosures

Number of shares issued (in shares) | shares

45,950

Equity issuance (in price per unit) | $ / shares

$ 60

Pre Funded Units

Common stock disclosures

Number of shares issued (in shares) | shares

208,096

Equity issuance (in price per unit) | $ / shares

$ 59.70

Pre Funded Units | 2018 Series A Warrant

Common stock disclosures

Number of shares/warrants comprised in a unit (in shares) | shares

1

Pre Funded Units | 2018 Series B Warrant Exercise price $.01

Common stock disclosures

Number of shares/warrants comprised in a unit (in shares) | shares

1

Pre Funded Units | Common Stock

Common stock disclosures

Number of shares of common stock to be purchased by each warrant | shares

1

Underwritten public offering during November, 2019.

Common stock disclosures

Number of shares issued (in shares) | shares

233,341

Equity issuance (in price per unit) | $ / shares

$ 3.60

Proceeds from issuance of common stock and warrants, net of issuance costs

$ 367,000

Underwritten public offering during November, 2019. | Placement Agent Warrants

Common stock disclosures

Exercise price (in dollars per unit) | $ / shares

$ 4.50

Number of Warrants | shares

15,168

Underwritten Public Offering March 2020 [Member]

Common stock disclosures

Number of shares issued (in shares) | shares

955,613

Underwritten Public Offering March 2020 [Member] | Series B Warrants 2020 [Member]

Common stock disclosures

Equity issuance (in price per unit) | $ / shares

$ 2.74999

Underwritten Public Offering March 2020 [Member] | Common Stock

Common stock disclosures

Equity issuance (in price per unit) | $ / shares

$ 2.75

Purchase and registration rights agreement | Common Stock

Common stock disclosures

Number of shares issued (in shares) | shares

574

0

Aggregate proceeds could be received

$ 15,000,000

Term

24 months

Deferred offering costs

$ 627,000

Purchase and registration rights agreement | Common Stock | Maximum

Common stock disclosures

Aggregate number of shares reserved for issuance | shares

40,000

Wainwright 2020 Placement Agent Warrants [Member]

Common stock disclosures

Percentage of warrants issued as a percentage of the warrants issued to the investors

6.50%

Proceeds from issuance of common stock and warrants, net of issuance costs

$ 6,000,000

Ladenburg Warrant Amendment [Member]

Common stock disclosures

Fair value adjustment of warrants

$ 764,000

Warrant reclassified to equity

$ 14,700,000

Ladenburg Warrant Amendment [Member] | 2018 Series B Warrant Exercise price $.01

Common stock disclosures

Shares issued on exercise of warrants | shares

0

Ladenburg Warrant Amendment [Member] | Series A Warrants [Member]

Common stock disclosures

Fair value adjustment of warrants

$ 666,000

Proceeds from exercise of warrants

$ 286,000

Shares issued on exercise of warrants | shares

0

0

40,975

0

COMMON STOCK, TRANSACTIONS, OTH

COMMON STOCK, TRANSACTIONS, OTHER (Details) $ in Thousands	Feb. 11, 2020	Apr. 16, 2018	Jan. 31, 2019shares	Jun. 30, 2020shares	Jun. 30, 2019shares	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)shares
Common stock disclosures
Stock issued under ESPP (in shares)			36
Proceeds from issuance of stock under ESPP | $							$ 1
Reverse stock split ratio	0.0333	0.04
Issuance of common stock upon vesting of restricted stock units (in shares)				50	21	50	48
Proceeds from exercise of warrants | $						$ 343
Common Stock
Common stock disclosures
Stock issued under ESPP (in shares)						0	36
Stock issued during period, shares, reverse stock splits						7,692
Issuance of common stock upon vesting of restricted stock units (in shares)				50	21	50	48

SHARE-BASED COMPENSATION, STO_3

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2019	Apr. 30, 2015	Mar. 31, 2015
Stock options
Expected term					10 years
Vesting period					48 months
Stock issued under ESPP (in shares)		36
Stock-based compensation (in dollars)			$ 45	$ 68	$ 115	$ 135
Stock Options
Stock options
Stock-based compensation (in dollars)			$ 21	$ 43	$ 64	$ 84
2010 Plan
Stock options
Granted (in shares)							0
Expected term					10 years
2015 Plan
Stock options
Shares available for future grants			26,670		26,670
Shares authorized for issuance									5,333
Expected term					10 years
2015 Plan Amendment [Member]
Stock options
Shares authorized for issuance	32,000
Increase in shares of common stock reserved for issuance (in shares)	26,667
2007 Plan
Stock options
Expected term					10 years
Employee Stock Purchase Plan
Stock options
Shares authorized for issuance										250
Aggregate number of shares reserved for issuance			264		264			264
Increased share reserve					67
Offering Period		6 months
Stock-based compensation (in dollars)					$ 0
Common Stock
Stock options
Stock issued under ESPP (in shares)					0	36

SHARE-BASED COMPENSATION, STO_4

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES, SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock options
Stock-based compensation (in dollars)	$ 45	$ 68	$ 115	$ 135
Expected term			10 years
Vesting period			48 months
Research and development
Stock options
Stock-based compensation (in dollars)	7	26	$ 27	50
General and administrative
Stock options
Stock-based compensation (in dollars)	38	42	88	85
Stock Options
Stock options
Stock-based compensation (in dollars)	$ 21	$ 43	$ 64	$ 84

SHARE-BASED COMPENSATION, STO_5

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES, ASSUMPTIONS USED IN DETERMINING THE FAIR VALUE (Details) - Stock Options	6 Months Ended
	Jun. 30, 2019
Assumptions used principally in determining the fair value of options granted
Risk-free interest rate (as a percent)	2.55%
Expected dividend yield (as a percent)	0.00%
Expected term (employee grants)	6 years
Expected volatility (as a percent)	105.00%

SHARE-BASED COMPENSATION, STO_6

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES, SUMMARY OF OPTION ACTIVITY - (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Option activity disclosures
Weighted Average Remaining Contractual Term - Outstanding			7 years 7 months 24 days		8 years 2 months 1 day
Weighted Average Remaining Contractual Term - Vested			6 years 9 months 29 days
Stock Option
Stock-based compensation (in dollars)	$ 45	$ 68	$ 115	$ 135
Stock Options
Summary of option activity - Shares
Outstanding at the beginning of year (in shares)			4,187
Outstanding at the end of period (in shares)	4,187		4,187		4,187
Vested at the end of period (in shares)			(2,061)
Summary of option activity - Weighted Average Exercise Price
Outstanding at the beginning of year (in dollars per shares)			$ 1,077.78
Outstanding at the end of period (in dollars per shares)	$ 1,077.78		1,077.78		$ 1,077.78
Vested at the end of period (in dollars per share)	$ 2,022.20		$ 2,022.20
Stock Option
Total fair value of options vested	$ 24	33	$ 80	69
Stock-based compensation (in dollars)	21	$ 43	64	$ 84
Total unrecognized compensation expense	$ 116		$ 116
Period for unrecognized compensation expense is estimated to be recognized			1 year 2 months 16 days

SHARE-BASED COMPENSATION, STO_7

SHARE-BASED COMPENSATION, STOCK OPTIONS, AND RESTRICTED SECURITIES, RESTRICTED STOCK (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based compensation
Stock-based compensation (in dollars)	$ 45	$ 68	$ 115	$ 135
Restricted Securities
Number of Grants
Unvested balance at			7,086
Vested/Released (in shares)			(50)
Unvested balance at	7,036		7,036
Weighted-Average Grant Date Fair Value
Unvested balance at (in dollars per share)			$ 33.78
Unvested balance at (in dollars per share)	$ 29.34		$ 29.34
Share-based compensation
Stock-based compensation (in dollars)	$ 24	$ 25	$ 51	$ 51
Unrecognized compensation
Total unrecognized compensation expense	$ 177		$ 177
Period for unrecognized compensation expense is estimated to be recognized			1 year 9 months 22 days

WARRANTS (Details)

WARRANTS (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Nov. 30, 2019
Warrants to purchase common stock issued and outstanding
Number of Warrants	4,745,334
Weighted average exercise price	$ 7.08
Weighted average life in years	4 years 9 months 26 days
2014 Warrant Exercise price $11.75
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2014
Number of Warrants	11
Warrant Exercise Price	$ 352.50
Expiration date	May 9, 2021
Warrants 2016 [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2016
Number of Warrants	2,865
Warrant Exercise Price	$ 7,500
Expiration date	Mar. 18, 2021
2018 Series A Warrant
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2018
Number of Warrants	211,921
Warrant Exercise Price	$ 6.98		$ 6.98
Expiration date	Jun. 25, 2023
Warrants 2019 [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2019
Number of Warrants	15,168
Warrant Exercise Price	$ 4.50
Expiration date	Nov. 21, 2024
Warrants 2020, First [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	12,728
Warrant Exercise Price	$ 0.00001
Warrants 2020, Second [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	2,545,455
Warrant Exercise Price	$ 2.75
Expiration date	Mar. 10, 2025
Warrants 2020, Third [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	165,455
Warrant Exercise Price	$ 3.4375
Expiration date	Mar. 5, 2025
Warrants 2020, Fourth [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	1,680,240
Warrant Exercise Price	$ 1.62
Expiration date	Oct. 17, 2025
Warrants 2020, Fifth [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	111,491
Warrant Exercise Price	$ 2.1875
Expiration date	Apr. 15, 2025
Placement Agent Warrants
Warrants to purchase common stock issued and outstanding
Number of Warrants		165,455
Warrant Exercise Price		$ 3.4375

NET LOSS PER COMMON SHARE (Deta

NET LOSS PER COMMON SHARE (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Anti-dilutive
Total potentially dilutive securities (in shares)	4,756,557	260,261
Warrants.
Anti-dilutive
Total potentially dilutive securities (in shares)	4,745,334	255,781
Stock Options
Anti-dilutive
Total potentially dilutive securities (in shares)	4,187	4,187
Unvested RSUs
Anti-dilutive
Total potentially dilutive securities (in shares)	150	293
Unvested restricted stock awards
Anti-dilutive
Total potentially dilutive securities (in shares)	6,886

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - shares	Aug. 04, 2020	Jan. 31, 2020	Jun. 30, 2020	Feb. 11, 2020	Dec. 31, 2019	May 31, 2018	Apr. 30, 2018
Subsequent events
Common stock, authorized		500,000,000	16,666,667	16,666,667	16,666,667	25,000,000	4,000,000
2015 Plan Amendment [Member]
Subsequent events
Increase in shares of common stock reserved for issuance (in shares)		26,667
Subsequent event
Subsequent events
Common stock, authorized	50,000,000
Subsequent event | 2015 Plan Amendment [Member]
Subsequent events
Increase in shares of common stock reserved for issuance (in shares)	400,000